Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label single-arm study of lomitapide in pediatric homozygous familial hypercholesterolemia
MOH_2020-11-17_008981Phase 3Active, not recruiting
- Sponsor
- Amryt Pharma
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lomitapide in homozygous familial hypercholesterolemia (HoFH), sponsored by Amryt Pharma. Primary endpoint: Percent change in LDL cholesterol. Started Jul 2020; status: active, not recruiting.
02
Drugs
lomitapide
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on MOH_2020-11-17_008981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-11-17_008981.